

Mouse Modeling in Oncologic Preclinical and Translational Research

Brett S. Carver^{1,2} and Pier P. Pandolfi^{1,3}

Abstract Through scientific and technological advancements, our ability to manipulate the mouse genome has allowed us to evaluate the effect of specific genetic alterations on *in vivo* tumorigenesis. This has allowed and will allow us to define molecular pathways describing the processes of tumor initiation, invasion, and progression to metastatic disease. Additionally, these models may serve as an excellent platform for the identification of novel molecular targets for therapy as well as to evaluate the efficacy of targeted therapies. Ultimately this will translate from preclinical mouse model trials to the development of clinical trials and protocols for cancer patients. Here we review the usefulness of mouse modeling in oncologic translational research.

With the identification of molecular pathways involved in tumorigenesis, novel models of human cancer have been developed to further our understanding, evaluate potential therapies, and ultimately impact on patient outcome. The mouse has provided an excellent platform for modeling cancer in a mammalian system. This has traditionally been accomplished with the use of xenograft models incorporating primary or genetically altered cell lines derived from primary and metastatic tumors. As our ability to manipulate the mouse genome expanded, it has become possible to evaluate specific molecular pathways involved in carcinogenesis. Currently, mouse modeling of human cancer is possible through the expression of oncogenes, specific genetic mutations, or the inactivation of tumor suppressor genes, and these experiments have begun to provide us with an understanding of the molecular pathways involved in tumor initiation and progression. Additionally, these mouse models serve as an excellent system to evaluate the efficacy of currently developed molecular targeted therapies and identify new potential targets for future therapies. To keep this review concise, we will focus on the generation and study of genetically altered mouse models for human acute promyelocytic leukemia (APL) and prostate cancer, two diseases that we currently study in our lab. Through this, we will show the usefulness of mouse models for oncologic and translational research.

From Human to Mice: Modeling Tumorigenesis

Through advances in the molecular analysis of human tumors, several well-defined and common molecular pathways have been found to be dysregulated in malignancies (1–3). As

knowledge was increasing about the identification of specific genetic alterations in cancers, our ability to manipulate the mouse genome was expanding. Broadly, genetically engineered mouse models of cancer encompass mice overexpressing a transgene (oncogene or point mutation), knock-in models of genetic point mutations, as well as complete knock-out and conditional knock-out models using the cre-lox system (4, 5). Taking advantage of the knowledge we have gained by examining genetic alterations in human malignancies, a number of studies have been done to evaluate the effect of these genetic alterations in mouse models (Fig. 1). These experiments have helped define the cellular responses to specific genetic alterations and their effect on the organismal phenotype. From these studies we have learned the mechanisms that confer selective advantage to tumor cells, such as disruption of cell cycle regulation and inhibition of apoptotic pathways. Whereas a number of mouse models have been generated and contributed greatly to the study of carcinogenesis, we have selected a few examples of mouse models of APL and prostate cancer to show their usefulness in establishing the molecular pathways involved in human tumorigenesis and their usefulness in translational research.

Modeling APL in the Mouse

APL accounts for >10% of all acute myelogenous leukemias and is characterized by distinct and unique features (6, 7). APL is associated with the accumulation in the bone marrow of tumor cells with promyelocytic features and the invariable association with specific reciprocal chromosomal translocations involving the retinoic acid receptor α ($RAR\alpha$) gene on chromosome 17 (6, 7). In the vast majority of cases (>98%), the $RAR\alpha$ gene fuses to the promyelocytic leukemia gene, PML . In a small subset of cases, $RAR\alpha$ has been found to fuse to several other genes that have recently been identified ($PLZF$, NPM , $NUMA$, or $STAT5b$) leading to the generation of X- $RAR\alpha$ and $RAR\alpha$ -X fusion proteins (8–11). The involvement of $RAR\alpha$ in the pathogenesis of APL made this leukemia a straightforward example of aberrant transcription in tumorigenesis. The RARs belong to the superfamily of nuclear hormone receptors, which act as transcription factors. These molecules are involved in fundamental biological processes, such as development and

Authors' Affiliations: ¹Cancer Biology and Genetics Program and Departments of ²Urology and ³Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York

Received 2/28/06; revised 6/21/06; accepted 6/27/06.

Requests for reprints: Pier Paolo Pandolfi, Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 110, New York, NY 10021. Phone: 212-639-6168; Fax: 212-717-3102; E-mail: p-pandolfi@ski.mskcc.org.

© 2006 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-06-0482




Fig. 1. Modeling cancer in mouse models allows investigators to generate accurate models of human malignancies through the expression of oncogenes, knock-in of genetic point mutations, and knock-out of tumor suppressors central to the human malignancy being studied.

differentiation. APL translocations result in the generation of *X-RAR α* and *RAR α -X* fusion genes and their coexpression in the leukemic blasts, resulting in the interference of both *RAR α* and *X*-gene pathways. To evaluate the role of these fusion proteins in leukemogenesis, a number of groups have attempted to generate mouse models that express these fusion proteins in the myeloid compartment of the bone marrow under the control of hemopoietic tissue-specific promoters (12–15). Through these efforts, it has been shown that the expression of PML-RAR α , PLZF-RAR α , NPM-RAR α , and NUMA-RAR α results in leukemic development in mice following a long latency and with variable penetrance. Additionally, these transgenic mice display distinct cytomorphologic features, depending on the fusion protein expressed. Transgenic mice expressing PML-RAR α develop leukemia with classic features of human APL following, however, a long latency with an approximate 10% to 30% penetrance (12, 13). By contrast, transgenic mice expressing the PLZF-RAR α fusion protein develop leukemia with chronic myelogenous leukemia-like features with 100% penetrance by 8 months of age (14). Strikingly, however, transgenic mice that coexpress both PLZF-RAR α and the reciprocal translocation product RAR α -PLZF develop leukemia with an APL phenotype. Thus, PLZF-RAR α confers a higher oncogenic potential than PML-RAR α but requires the presence of RAR α -PLZF to trigger an APL phenotype. Modeling APL through the overexpression of RAR α fusion proteins has provided concrete proof for the role of these proteins in leukemogenesis. Additionally, the specific translocation products contribute distinct molecular and morphologic features to the developing leukemia, which

may play a role in sensitivity to therapy, as we will discuss in the following section. Therefore, mouse models serve as an excellent platform for the molecular analysis of pathways involved in the initiation and progression of malignancies as well as the evaluation of therapeutic agents.

Modeling Prostate Cancer in the Mouse through the Loss of *PTEN*

The tumor suppressor gene phosphatase and tensin homologue (*PTEN*) is mutated in a variety of human malignancies at a frequency roughly equal to that of p53 (16). *PTEN*, a lipid phosphatase, is a negative regulator of the phosphatidylinositol 3-kinase/AKT pathway, which is frequently activated in a variety of malignancies. It has previously been reported that ~70% of primary prostate cancers show loss of at least one allele of *PTEN*, whereas homozygous inactivation of *PTEN* is generally associated with advanced cancer and metastases (17). In an effort to define the role of *PTEN* loss in prostate tumorigenesis, a series of *PTEN* loss mouse models (*PTEN*^{+/-}, *PTEN* hypomorphic, and *PTEN* conditional knock-out) have been generated. This has allowed us to determine the critical importance of subtle variations in the level of *PTEN* on prostate tumorigenesis. These analyses allowed us to reach a number of important conclusions: (i) Loss of *PTEN* is critical for prostate cancer initiation (18, 19). (ii) The level of *PTEN* expression is inversely associated with prostate tumorigenesis. For instance, loss of one allele of *PTEN* is associated with the development of high-grade prostatic intraepithelial neoplasia

(carcinoma *in situ*) with incomplete penetrance after a long latency, whereas when the PTEN level is reduced to ~30% (hypomorphic mouse model), invasive prostatic adenocarcinoma develops with incomplete penetrance. Furthermore, complete loss of PTEN results in the development of invasive prostate cancer with complete penetrance after a long latency (6 months of age); however, these tumors do not result in a shortened life span (19). Wang et al. (20) have also shown that prostate conditional loss of PTEN results in invasive prostate cancer. Additionally, these mice developed metastatic prostate cancer of the lymph nodes and lung, which was not observed in our PTEN loss mouse model. This may be, perhaps, secondary to the different genetic background strain of the mice, which is known to influence cancer susceptibility. Taken together, these studies have shown that loss of PTEN *in vivo* results in activation of the AKT pathway and susceptibility to tumorigenesis, which is closely related to the degree of PTEN insufficiency. (iii) Additionally, loss of PTEN has been shown to cooperate with the loss of other tumor suppressors frequently found inactivated in prostate cancer (p27 and p53) to accelerate tumorigenesis (21, 22). Mice nullizygous for *PTEN* and *p53* in the prostate (prostate conditional knock-out) develop a locally aggressive, lethal prostate cancer, with a complete penetrance. Importantly, through this research, we have learned that PTEN and p53 cooperate in a specific manner to accelerate tumorigenesis. Complete loss of PTEN triggers, in fact, a fail-safe cellular response to oncogenic stress, known as cellular senescence, which occurs through a p53-dependent mechanism (Fig. 2; ref. 22). Cellular senescence describes an irreversible cell cycle arrest phenotype, which is triggered by cellular stress such as the activation of oncogenes. Thus, complete loss of PTEN in the prostate results in an indolent prostate cancer, due to the fact that PTEN inactivation in the prostate triggers *in vivo* a p53 cellular senescence response, thereby limiting the progression of cancer. Therefore, concomitant or sequential prostatic loss of PTEN and p53 results in a dramatic acceleration of prostate tumorigenesis.

As these examples undoubtedly prove, mouse models have allowed us to construct oncogenic pathways, potentially identifying a series of molecular events resulting in tumor initiation and subsequent progression to invasive disease. Understanding the multistep evolution from homeostasis to tumorigenesis to metastasis is paramount for defining therapies that would be effective at various clinical disease states.

Evaluation and Development of Targeted Therapy in Genetic Mouse Models and Genetically Engineered Primary Cells

With further understanding of the molecular pathways involved in tumorigenesis, there has been an explosion of research in the development and evaluation of potentially effective "targeted therapies," cancer drugs that target molecular processes thought to be critical of tumor initiation, survival, or progression. Ideally, these malignant processes can be identified before treatment through clinical and pathologic evaluation of the patient and tumor specimen. Arguably, the first form of targeted therapy was the use of antiestrogens in women with breast cancer that overexpressed the estrogen receptor (23, 24). Through immunohistochemical analysis of the tumor specimens, it was possible to identify a population of

breast cancer patients who would potentially benefit from antiestrogen therapy. Additionally, through the molecular analysis of APL, it was identified that a reciprocal chromosomal translocation, t(15;17), resulted in a RAR α fusion protein and subsequent RAR α functional impairment (25, 26). The development of all-*trans* retinoic acid therapy, targeting the wild-type RAR to induce cellular differentiation, has resulted in high overall response rates, delay in disease progression, and long-term cure rates in select patients with APL (26).

A critical event in the process of therapeutic testing is the preclinical evaluation in the animal model. Thus far, the majority of preclinical trials have been conducted in xenograft mouse models. Whereas xenograft models are straightforward and relatively easy to use, their accuracy in predicting the efficacy of an anticancer agent in patients is questionable (27). This may be secondary to cell line selection, the environment or location of the xenograft transplant, or the lack of *de novo* tumor development. Mouse models recapitulate human malignancies by *de novo* tumor development, preserving the organ microenvironment, and thus may provide an excellent setting to evaluate the efficacy of chemotherapeutic agents in a system with few additional genetic changes. To date, the most concrete example of this is the evaluation of novel therapies in APL mouse models, as we will discuss in the following paragraphs.

Another powerful drug testing/development tool that can be easily derived from accurate mouse models of cancer is represented by primary cells such as mouse embryonic fibroblasts (MEF), which is probably one of the purest and handiest genetic systems to evaluate targeted therapies and perform high-throughput drug screenings. MEF generated from a genetically modified mouse (e.g., a knock-out mouse lacking a tumor suppressor) carries the same genetic alteration, and although it may not be the cell of origin of the modeled phenotype, it allows us to readily evaluate the genetic and molecular processes resulting from the loss of a tumor suppressor or the overexpression of an oncogene. These cells also allow us to rapidly evaluate potential targeted therapies, the ability of a drug to hit its molecular target and its mechanism of action in various genetic backgrounds, as well as to identify new targets of interest (Fig. 3). A caveat exists with the use of MEF in that these cells, while providing excellent genetic and molecular evaluation, are frequently not the cells of origin for the majority of malignancies evaluated and, therefore, cellular specific processes may vary. Therefore, whereas MEF allows for the screening of molecular events and therapeutic strategies, experiments must be confirmed in the origin of the malignant cells in preclinical trials with mouse models.

In summary, the mouse model or primary cells derived from these mouse mutants can be effectively used for the development of novel therapeutic modalities. We will provide a few examples of the power of this approach and the impact that it has had on clinical practice in recent years.

PTEN-AKT Pathway: Examples of Target Inhibition in Genetically Engineered MEF and Mouse Models

Rapamycin, a bacterial macrolide, has been shown to inhibit the mammalian protein mammalian target of rapamycin (mTOR) kinase, which links mitogen stimulation to protein synthesis and cell cycle progression, and seems to be an




Fig. 2. From mouse modeling of PTEN loss, we have shown that haploinsufficiency is an early event in prostate tumorigenesis, resulting in the development of high-grade prostatic intraepithelial neoplasia. Complete loss of PTEN results in the progression to an invasive prostate cancer; however, in the presence of wild-type p53, a cellular senescence response is triggered, limiting further progression and resulting in a nonlethal, indolent form of the disease. Concomitant or sequential loss of p53 results in a lethal, dramatic acceleration of prostate cancer growth secondary to loss of the cellular senescence response.

attractive anticancer therapeutic target (28). Cancer initiation and progression frequently involves signaling pathways linked to mTOR, such as AKT or extracellular signal-regulated kinase activation, and several clinical trials are currently ongoing with rapamycin and its analogues in breast cancer, prostate cancer, and renal cell carcinoma. Several studies involving MEF have allowed investigators to determine the *in vitro* effectiveness of rapamycin in various genetic backgrounds, as well as the mechanisms of action in these cells. Rapamycin has been shown to induce a G₁ cell cycle arrest in wild-type MEF, which depends on intact *p53/p21* genes (29). This was determined by analyzing the effect of rapamycin on cells that have been genetically modified to be nullizygous for *p53* or *p21*. It was shown that *p53*- or *p21*-null MEFs have a diminished ability to undergo G₁ cell cycle arrest and instead elicit an apoptotic response to rapamycin treatment (29). Due to the frequency of *p53* mutations in human malignancies often coexisting with mutations in genes regulating the mTOR axis, this may in part explain why a molecular targeted therapy, such as rapamycin, confers selectivity to tumor cells and relatively spares normally proliferating cells.

Along the same line, it has been shown that loss of PTEN in both mouse cells and mouse tumors results in an increased activity of mTOR leading to S6 kinase activation, and inhibition of the mTOR pathway with the rapamycin analogue CCI-779 was capable of blocking tumor development (30, 31). Xing and

Orsulic further showed, using mouse ovarian epithelial cells expressing the TVA receptor, that specific genetic alterations could be generated in these cells with the RCAS system (32), and furthermore, that rapamycin effectively inhibited the growth of ovarian tumors *in vivo*, which relied on AKT signaling for proliferation (33). Thus, the use of mouse models allowed us to evaluate the effect of a specific targeted therapy in the face of known genetic alterations.

In addition to the evaluation of various targeted therapies, altering the genetics of the mouse will allow us to identify molecular pathways that may be useful targets for future therapeutic development. As we have previously stated, p53 elicits a cellular senescence response following the loss of PTEN and subsequent activation of AKT. Additionally, loss of p53 in these mouse models accelerates tumorigenesis, confirming the importance of p53 in this oncogenic pathway. Based on these findings, it is attractive to conclude that therapies up-regulating or stabilizing p53 may be effective in *PTEN*-null tumors early in the process of tumorigenesis before p53 gets lost or mutated. Small-molecule inhibitors that bind to the p53 pocket of murine double minute-2, thereby inhibiting p53 degradation, have been developed (34). This class of p53-enhancing drugs has broad implications as a number of initiation events in cancer development trigger a p53 response, which is frequently overcome by p53 loss. Therefore, stabilization of functional

p53 may lead to cell cycle arrest or cellular death, and this may be particularly effective in the context of *PTEN* nullizygosity.

With our enhanced knowledge of pathways involved in cancer initiation and progression, a number of molecules seem to be attractive targets of therapy in malignancies with loss of *PTEN* (Fig. 4). These targets can be easily modeled in knock-out mice to determine their effect on tumorigenesis and whether a screening for potential drugs to inhibit these pathways should be undertaken.

Acute Promyelocytic Leukemia: Evolution of Preclinical Trials

Mouse modeling has been effectively used to evaluate a variety of therapeutic agents for the treatment of APL. From these studies we have gained a substantial knowledge as to which therapies are efficacious and to which degree the molecular basis for the leukemia dictates the response to therapy. As in humans, APL in PML-RAR α transgenic mice responds well to retinoic acid therapy, which can induce complete disease remission; hence, this mouse model faithfully recapitulates the human form of the disease, not only in its genetics but also in the responsiveness to therapy (35). Through these preclinical studies, we have also found that leukemic mice harboring the

PLZF-RAR α fusion protein poorly respond to retinoic acid, and complete disease remission is never attained (35). Therefore, patients with APL who harbor the t(11;17) translocation are not ideal candidates for retinoic acid therapy. Furthermore, additional preclinical studies have shown that the addition of arsenic trioxide to retinoic acid therapy improved survival in PML-RAR α transgenic mice (35, 36). This is of importance in that previous investigators concluded that, on the basis of *in vitro* studies, no synergistic effect would result from combination therapy with retinoic acid and arsenic trioxide. Therefore, the efficacy of this combination therapy for APL, which is now in clinical trials, highlights the benefits of mouse modeling. However, no benefit was seen for single or combination therapy in PLZF-RAR α transgenic mice, showing the resistant nature of these leukemias. Given that the PML-RAR α and PLZF-RAR α fusion proteins function as aberrant transcriptional repressors, in part by recruiting nuclear receptor-transcriptional corepressors and histone deacetylases, the efficacy of histone deacetylase inhibitors for the treatment of APL has been evaluated (37). In APL cells harboring the t(15;17) translocation, histone deacetylase inhibitors cause growth inhibition and apoptosis and potentiate retinoic acid-induced differentiation. Furthermore, whereas retinoic acid therapy is not efficacious for the treatment of APL induced by the PLZF-RAR α fusion protein, combination




Fig. 3. MEFs represent an excellent tool for the evaluation of therapies in various genetic backgrounds, as well as the screening of novel therapies through the use of RNA interference or small-molecule inhibitors. Therapies that result in an efficacious response can then be evaluated in preclinical trials using mouse models that faithfully recapitulate the human form of the disease.




Fig. 4. Targeting a malignancy, such as prostate cancer, which shows the loss of PTEN can be accomplished with combination targeted therapy. Rapamycin, an inhibitor of mTOR kinase, could potentially be combined with nutlin, a murine double minute-2 inhibitor, if molecular characterization of the tumor shows a functional p53.

therapy with retinoic acid and a histone deacetylase inhibitor prolonged survival and induced complete remission in transgenic mice without noticeable toxicity (37). On the basis of these results, histone deacetylase inhibitors have subsequently been used in the treatment of human APL (38). From these studies we have gained information about the mechanism of action of these therapeutic agents as well as the molecular setting in which they are most efficacious (Table 1). This will ultimately lead to clinical trials evaluating these therapeutic agents in appropriate patients based on molecular and cytogenetic criteria.

From Mice to Humans: The Evolution of Clinical Trials

Mouse models have continued and will continue to provide us with a wealth of information about tumor initiation and prog-

ression, potential novel targets and markers of therapy, and the efficacy and tolerance of various anticancer agents. The translation of this data is of paramount importance to improve our ability to prognosticate and ultimately render cancer patients free of disease. With the identification of molecular markers and their role in the process of tumorigenesis, it is currently possible to molecularly stage a cancer patient. Through this, clinicians are capable of identifying patients who would be candidates for enrollment in a targeted therapy clinical trial. This strategy was initially employed for women with breast cancer (23, 24). Following examination of the tumor specimen, clinical trials have shown that women with estrogen receptor/progesterone receptor-positive tumors receive a substantial benefit from adjuvant antiestrogen (tamoxifen) therapy. More recently, gefitinib, a tyrosine kinase inhibitor that has shown efficacy for non-small-cell lung cancers, has emerged as an excellent model of targeted

Table 1. Response to targeted therapy in mouse models of APL

Genetic modification	Response to RA	Response to RA + As ₂ O ₃	Response to RA + HDAC inhibitor
PML-RAR α	CR	CR	CR
PLZF-RAR α	NR	NR	CR
NPM-RAR α	CR	—	—

Abbreviations: RA, retinoic acid; As₂O₃, arsenic trioxide; HDAC, histone deacetylase; CR, complete response; NR, nonresponsive.

therapy. It has recently been shown that specific mutations in the epidermal growth factor receptor confer sensitivity to gefitinib therapy (39–41). Therefore, molecular characterization of these tumors is essential for dictating appropriate therapy.

As we discussed before, APL patients with PML-RAR α respond to all-*trans* retinoic acid therapy. Taken what we have learned from preclinical studies in APL transgenic mice, the combination of retinoic acid and arsenic trioxide therapy is a reasonable form of therapy for patients relapsing following conventional therapy, who harbor the t(15;17) translocation, and more importantly, clinical trials are currently under way evaluating this combination therapy for the primary management of APL (42–44).

It is therefore obvious that future trials evaluating chemotherapeutic agents for cancer patients should incorporate cytogenetic and molecular markers, as mouse modeling has shown that response to therapy is dictated by the molecular and genetic makeup of the tumor. With the emergence of more data showing the efficacy of targeted therapies in preclinical mouse models, future clinical trials will be designed for cancer patients. In this respect, mouse modeling of APL represents a compelling example for the ideal progression from preclinical evaluation to translational research and has successfully informed clinical trials and altered the management of patients.

References

1. Balmain A, Harris C. Carcinogenesis in mouse and human cells: parallels and paradoxes. *Carcinogenesis* 2000;21:371–7.
2. Cohen BA, Mitra RD, Hughes JD, Church GM. A computational analysis of whole-genome expression data reveals chromosomal domains of gene expression. *Nat Genet* 2000;26:183–6.
3. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. *Cell* 2002;108:153–64.
4. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. *Cell* 2002;108:135–44.
5. Adams JM, Cory S. Transgenic models of tumor development. *Science* 1991;254:1161–7.
6. Warrell RP, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. *N Engl J Med* 1993;329:177–89.
7. Melnick A, Licht JD. Deconstructing a disease: RAR α , its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. *Blood* 1999;93:3167–215.
8. Kakizuka A, Miller WH, Jr., Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR α with a novel putative transcription factor, PML. *Cell* 1991;66:663–74.
9. Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor- α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. *EMBO J* 1993;12:1161–7.
10. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. *Nat Genet* 1997;17:109–13.
11. Arnould C, Philippe C, Bourdon V, Gr goire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukaemia. *Hum Mol Genet* 1999;8:1741–9.
12. He LZ, Tribioli C, Rivi R, et al. Acute leukemia with promyelocytic features in PML/RAR α transgenic mice. *Proc Natl Acad Sci U S A* 1997;94:5302–7.
13. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR α under control of cathepsin G regulatory sequences. *Blood* 1997;89:376–87.
14. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RAR α and PLZF-RAR α with co-repressors determine differential responses to RA in APL. *Nat Genet* 1998;18:126–35.
15. Cheng GX, Zhu XH, Men XQ, et al. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RAR α and NPM-RAR α . *Proc Natl Acad Sci U S A* 1999;96:6318–23.
16. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumor suppressor gene MMAC1 at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nat Genet* 1997;15:356–62.
17. Gray IC, Stewart LM, Phillips SM, et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. *Br J Cancer* 1998;78:1296–300.
18. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumor suppression. *Nat Genet* 1998;19:348–55.
19. Trotman LC, Niki M, Dotan ZA, et al. Pten dose dictates cancer progression in the prostate. *PLoS Biol* 2003;1:385–96.
20. Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell* 2003;4:209–21.
21. Di Cristofano A, DeAcetis M, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27 kip1 cooperate in prostate cancer tumor suppression in the mouse. *Nat Genet* 2001;27:222–4.
22. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature* 2005;436:725–30.
23. Ciocca DR, Elledge R. Molecular markers for predicting response to Tamoxifen in breast cancer patients. *Endocrine* 2000;13:1–10.
24. Locker GY. Hormonal therapy of breast cancer. *Cancer Treat Rev* 1998;24:221–40.
25. Parmar S, Tallman MS. Acute promyelocytic leukemia: a review. *Expert Opin Pharmacother* 2003;4:1379–92.
26. Fang J, Chen SJ, Tong JH, et al. Treatment of acute promyelocytic leukemia with ATRA and As₂O₃: a model of molecular target-based cancer therapy. *Cancer Biol Ther* 2002;1:614–20.
27. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the *in vitro* cell line, human xenograft, and mouse allograft preclinical cancer models. *Clin Cancer Res* 2003;9:4227–39.
28. Liu M, Howes A, Lesperance J, et al. Antitumor activity of rapamycin in a transgenic mouse model of Erb2-dependent human breast cancer. *Cancer Res* 2005;65:5325–36.
29. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21 cooperate in enforcing rapamycin-induced G₁ arrest and determine the cellular response to rapamycin. *Cancer Res* 2001;61:3373–81.
30. Neshat MS, Mellingshoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. *Proc Natl Acad Sci U S A* 2001;98:10314–9.
31. Podsypania K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN^{+/-} mice. *Proc Natl Acad Sci U S A* 2001;98:10320–5.
32. Fisher GH, Orsulic S, Holland E, et al. Development of a flexible and specific gene delivery system for production of murine tumor models. *Oncogene* 1999;18:5253–60.
33. Xing D, Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. *Proc Natl Acad Sci U S A* 2005;102:6936–41.
34. Vassilev LT, Vu BT, Graves B, et al. *In vivo* activation of the p53 pathway by small-molecule antagonists of MDM2. *Science* 2004;303:844–8.
35. Rego EM, He LZ, Warrell RP, Jr., Wang ZG, Pandolfi PP. Retinoic acid (RA) and As₂O₃ treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RAR α and PLZF-RAR α oncoproteins. *Proc Natl Acad Sci U S A* 2000;97:10173–8.
36. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. *J Exp Med* 1999;189:1043–52.
37. He LZ, Tolentino T, Grayson P, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. *J Clin Invest* 2001;108:1321–30.
38. Warrell RP, Jr., He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. *J Natl Cancer Inst* 1998;90:1621–5.
39. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004;101:13306–11.
40. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2:73.
41. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129–39.
42. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. *N Engl J Med* 1998;339:1341–8.
43. Shen ZX, Shi ZZ, Fang J, et al. All-*trans* retinoic acid/As₂O₃ combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. *Proc Natl Acad Sci U S A* 2004;101:5328–35.
44. Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-*trans*-retinoic acid in patients with relapsed acute promyelocytic leukemia. *J Clin Oncol* 2003;21:2326–34.

Clinical Cancer Research

Mouse Modeling in Oncologic Preclinical and Translational Research

Brett S. Carver and Pier P. Pandolfi

Clin Cancer Res 2006;12:5305-5311.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/12/18/5305>

Cited articles This article cites 44 articles, 17 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/12/18/5305.full#ref-list-1>

Citing articles This article has been cited by 7 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/12/18/5305.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/12/18/5305>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.